

FINDING OPPORTUNITY



2021
ANNUAL REPORT



BECAUSE OF SUPPORTERS LIKE YOU,

WE MADE GREAT PROGRESS IN 2021



More than
2.5 MILLION PEOPLE
served through education
programs, digital resources,
and support services



Provided more than
**70 FREE PATIENT
AND PROFESSIONAL
PROGRAMS**

Nearly
**20,000 PATIENTS,
SURVIVORS,
AND CAREGIVERS**
supported through the
LRF Helpline



29 NEW GRANTS
awarded and more than
51,000 research hours
funded—enabling early-
career scientists to maintain
a research focus on lymphoma



People in all
50 STATES
(plus the District of Columbia)
and in more than
150 COUNTRIES
accessed LRF digital resources



Since our founding, the Lymphoma Research Foundation (LRF) has been leading the way to create a world without lymphoma.

After more than a quarter century, we remain committed to funding the best science and serving the lymphoma community through education, support, and compassion. We are grateful to the scientists who partner with LRF to move the research needle forward and advance our understanding of the more than 100 different lymphoma subtypes. We are thankful for our corporate partners, donors, and volunteers who support the Foundation's vital work and make progress possible.



"The Lymphoma Research Foundation helps advance life-saving research, helping fund crucial clinical trials and research endeavors that have contributed to many FDA approvals and advancement in the field."



Anita Kumar, MD
Memorial Sloan
Kettering Cancer Center,
Two-Time LRF Grantee



LETTER FROM THE CEO & CHAIR OF THE BOARD

Dear Friends,

We are excited to share the progress made by the Lymphoma Research Foundation (LRF) over the past year. This report highlights many of the Foundation's achievements during this time, all made possible by the unwavering commitment of LRF supporters.

But this report is not only a story of progress; it is a story of opportunity and the people behind these accomplishments. Opportunity is a theme that resonates throughout this report and in everything we do. LRF is in constant search of opportunity: The opportunity to help patients and caregivers in need; to support the next generation of lymphoma scientists; and to advance life-saving research. As you will read, we sought to accomplish this important work by prioritizing health equity through Spanish-language programming and scientific workshops addressing the challenges faced by underrepresented populations. As such, we created a collaborative scientific research mentoring program, using our convening power to establish the nation's only COVID-19 and Lymphoma Panel, and expanded digital programs to better serve lymphoma patients, healthcare professionals, and researchers alike.

The LRF mission to eradicate lymphoma forever is driven by and for people: People who research, treat, and support those affected by this disease. We are fortunate to have trusted supporters and partners who provide resources that enable us to pursue these opportunities and serve those touched by this disease.

With gratitude,



Meghan Gutierrez
Chief Executive Officer



Steven Eichberg
Chair, Board of Directors



Steven Eichberg
Chair, Board of Directors



Meghan Gutierrez
Chief Executive Officer

OUR MISSION

To eradicate lymphoma and serve all those touched by this disease.

OUR FOCUS

Devoted exclusively to funding lymphoma research and supporting the lymphoma community through evidence-based education, support services, and resources.



Research

Our disease specificity and hyperfocus on finding cures for every type of lymphoma ensure the next generation of cancer researchers dedicate their careers to studying lymphoma.



Education & Support

We lead the way in ensuring patients and their loved ones have the support and knowledge they need to make informed decisions about their care.



Awareness & Advocacy

Awareness and advocacy are vital in our effort to increase the public's understanding of this disease, increase federal investment in lymphoma research, and improve patient outcomes.



"The Lymphoma Research Foundation (LRF), and the work it does, is critical in supporting people with lymphoma and their loved ones, and the next generation of scientists. Although significant progress has been made, we are not curing everybody, nor are we helping everyone to live to their best potential. We need to continue to conduct research until that happens, and LRF is the driving force to accelerating cures as well as ensuring that no one faces this disease alone."



Sonali M. Smith, MD, FASCO

The University of Chicago
Chair, LRF Scientific Advisory Board

OUR IMPACT

With a patient-focused approach and unique access to lymphoma experts, the Lymphoma Research Foundation (LRF) is the organization of choice for businesses, foundations, and individuals looking to make an impact in the pursuit of cures for lymphoma.

Our exceptional education resources for the lymphoma community and investment in the most promising research have cemented us as a trusted resource and respected partner among lymphoma patients and their loved ones, researchers, clinicians, and policymakers.

"Through the Lymphoma Research Foundation, I've learned that sharing my story makes a tremendous impact and is a unique way of addressing the immediate need of someone newly diagnosed—the need for hope. By connecting with patients, I can help calm some of their anxiety. I've also learned so much about research. The lymphoma I have is so rare, yet it amazes me the amount of research being done, due largely to the work of LRF. The Foundation saves lives in so many ways."



Shelia Johnson
Cutaneous T-cell Lymphoma
Survivor



ACHIEVEMENTS IN 2021



Research

- Funded 29 new grants—including 14 scholars in the **newly expanded Lymphoma Scientific Research Mentoring Program (LSRMP)**—enabling early-career scientists to maintain a research focus on lymphoma.
- Convened the **first-ever Transformed Lymphomas Scientific Workshop**, bringing together a select group of experts in chronic lymphocytic leukemia/Richter's transformation, transformed follicular lymphoma, and transformed marginal zone lymphomas, to discuss pressing issues in research and development of better treatment strategies for patients.
- Established the **COVID-19 and Lymphoma Initiative** to regularly convene a panel of experts in the fields of lymphoma, epidemiology, infectious disease, and public health to contribute to the body of evidence on this important subject and bring attention to the needs of the lymphoma community.
- Launched the **Health Equity Initiative** with the goal of removing barriers and creating opportunities so that researchers and clinicians can pursue—and every person can access—quality healthcare.
- **Jacob Soumerai, MD**, of Massachusetts General Hospital presented data at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition. This study, funded in part by LRF, showed that minimal residual disease (MRD) kinetics is a good predictor of achievement and durability of undetectable MRD with BOVen treatment in patients with chronic lymphocytic leukemia (CLL).




Education & Support

- **Served more than 2.5 million people** through education programs, digital resources, and support services.
- **Launched *Lymphoma.org en Español*** and expanded our lymphoma education resources and programming to address the language and ethnic discordance seen in existing disease materials and other resources that create barriers to effective communication of lymphoma information for the Spanish-speaking community.
- **Provided more than 70 free patient and professional education programs**, ensuring patients and their loved ones have the most up-to-date information on their type of lymphoma, and practicing physicians stay up to date on issues specific to the diagnosis and treatment of their lymphoma patients.
- The **LRF Helpline supported nearly 20,000 people**, offering patients, survivors, and caregivers resources and services in a critical time of need.
- The **Lymphoma Support Network grew to more than 7,000 volunteers** who share their lymphoma stories and provide peer support to patients and their loved ones.



Awareness & Advocacy

- Mobilized LRF Advocates to raise their collective voices in support of greater investment in cancer research. Congress listened, **allocating \$6.56 billion to the National Cancer Institute (NCI)**—a \$119 million increase over the fiscal year 2020 regular and Cancer Moonshot appropriations.
- Joined blood cancer organizations to urge the Advisory Committee on Immunization Practices at the Centers for Disease Control and Prevention (CDC) to **prioritize the COVID-19 vaccination for blood cancer patients and other immunocompromised people**.
- **Reached more than 30 million people** through ***Light it Red for Lymphoma***, our LRF Blood Cancer Awareness Month Initiative.
- **More than 3,000 people nationwide joined Team LRF** to raise funds to support life-saving research and provide hope to all those impacted by lymphoma.



FINDING OPPORTUNITY: RESEARCH

We are privileged to work with the leading minds in lymphoma research—our elite Scientific Advisory Board (SAB), which guides our research programs. These dedicated experts convene annually to help us find opportunities where the Lymphoma Research Foundation can make the biggest impact—from investing in the best and brightest researchers, to facilitating collaboration and partnerships among academic scientists, clinicians, and government and regulatory agencies to discuss the state of lymphoma research and patient care.



GLOBAL SCIENTIFIC IMPACT

Through our global lymphoma consortia, research initiatives, and scientific workshops, we mobilize the research community to overcome systemic challenges and accelerate the development of new treatments for lymphoma and chronic lymphocytic leukemia (CLL).

In March 2021, we convened experts in the fields of lymphoma, epidemiology, infectious disease, and public health for the inaugural COVID-19 and Lymphoma Panel. The purpose of the panel was to discuss the state of research regarding the COVID-19 vaccine and people with lymphoma. Proceedings from the panel regarding future areas of discovery and scientific research influenced the Centers for Disease Control and Prevention (CDC) vaccine recommendations for immunocompromised people, providing better guidance for lymphoma patients and their loved ones. Due to the astounding impact of the inaugural panel and rapidly shifting pandemic, the COVID-19 and Lymphoma Panel began to meet monthly in Fall 2021 to stay on the cutting edge and ensure the needs of the lymphoma community are met.



Awarded
29 RESEARCH GRANTS
totaling more than
\$2 MILLION


COMMITMENT TO EARLY-CAREER SCIENTISTS

In 2021, we awarded 29 research grants, totaling more than \$2 million, to early-career scientists—the only private foundation to do so in 2021. Our grantee class represents the world's leading cancer research institutions in North America, covering various disease subtypes, treatments, and cohorts, including T-cell lymphomas, B-cell lymphomas, adolescent and young adult lymphoma, and chimeric antigen receptor (CAR) T-cell therapy. Among this class are translational researchers in the newly expanded Lymphoma Scientific Research Mentoring Program (LSRMP). The addition of a translational track in the LSRMP will foster and develop the next generation of laboratory and translational researchers, bridge the network among clinical researchers, and provide them with the tools and knowledge needed to develop successful clinical trials in lymphoma.

Transformed lymphomas are typically associated with the rapid progression of CLL and often have a poor prognosis. The underlying biology of transformation is not fully understood, and there are limited educational resources and clinical trials dedicated to this patient population.

In August 2021, we convened a select group of researchers, regulatory officials, and industry representatives for the inaugural Transformed Lymphomas Scientific Workshop to discuss pressing issues with CLL, Richter's transformation, transformed follicular lymphoma (FL), and transformed marginal zone lymphoma (MZL). Recommendations from this two-day virtual program will profoundly inform research, the development of better treatment strategies, and educational programming—providing a huge step forward in supporting those impacted by this disease.


MEET OUR GRANTEES



Pamela B. Allen, MD
Winship Cancer Institute of Emory University

CAREER DEVELOPMENT AWARD

Lymphoma Focus: Mycosis fungoides, primary cutaneous T-cell lymphoma, Sézary syndrome



Jamie Flerlage, MD
St. Jude Children's Research Hospital

CAREER DEVELOPMENT AWARD


Lymphoma Focus: Hodgkin lymphoma, pediatric and adolescent/young adult (AYA) lymphoma



Tomohiro Aoki, PhD
BC Cancer Research Centre

LRF SCHOLAR

Lymphoma Focus: Hodgkin lymphoma



Rui Guo, MS, PhD
Brigham and Women's Hospital,
Harvard Medical School

POSTDOCTORAL FELLOWSHIP GRANT

Lymphoma Focus: Burkitt lymphoma



Elena Battistello, PhD
NYU Grossman School of Medicine

POSTDOCTORAL FELLOWSHIP GRANT

Lymphoma Focus: T-cell lymphoma



Rosella Marullo, MD, PhD
Weill Cornell Medicine

LRF SCHOLAR


Lymphoma Focus: Diffuse large B-cell lymphoma



David A. Bond, MD
The Ohio State University Comprehensive
Cancer Center

ERIC COHEN DISTINGUISHED SCHOLAR

Lymphoma Focus: Diffuse large B-cell lymphoma



Alexandre Hirayama, MD
Fred Hutchinson Cancer Research Center

POSTDOCTORAL FELLOWSHIP GRANT

Lymphoma Focus: Diffuse large B-cell lymphoma



Lydie Debaize, PhD
Dana-Farber Cancer Institute

POSTDOCTORAL FELLOWSHIP GRANT


Lymphoma Focus: B-cell lymphoma, mantle cell lymphoma



Hannah Isles, PhD
Weill Cornell Medicine

POSTDOCTORAL FELLOWSHIP GRANT

Lymphoma Focus: Diffuse large B-cell lymphoma, marginal zone lymphoma



Kathleen Dixon, PhD
University of Minnesota Twin Cities

POSTDOCTORAL FELLOWSHIP GRANT

Lymphoma Focus: Non-Hodgkin lymphoma, B-cell lymphoma



P. Connor Johnson, MD
Massachusetts General Hospital Cancer Center

**STEPHANIE A. GREGORY MD, FACP,
DISTINGUISHED SCHOLAR**

Lymphoma Focus: Aggressive non-Hodgkin lymphoma



Zachary Epstein-Peterson, MD
Memorial Sloan Kettering Cancer Center

LRF SCHOLAR


Lymphoma Focus: T-cell lymphoma



Richa Kapoor, PhD
University of Pennsylvania Perelman
School of Medicine

POSTDOCTORAL FELLOWSHIP GRANT


Lymphoma Focus: T-cell lymphoma



Edmond Ferris, PhD
Dartmouth-Hitchcock Norris Cotton Cancer Center

POSTDOCTORAL FELLOWSHIP GRANT

Lymphoma Focus: B-cell lymphoma, T-cell lymphoma




Niloufer Khan, MD, MS
Memorial Sloan Kettering Cancer Center



LRF SCHOLAR

Lymphoma Focus: Primary cutaneous T-cell lymphoma, Sézary syndrome

"The Lymphoma Research Foundation (LRF) has been part of my lymphoma journey since day one, and I look forward to helping them make an impact on the lymphoma community. I feel confident the Runge Lymphoma Project's investment in LRF's mentoring program will prove dividends in lymphoma research."



Matt Runge, Founder of the Runge Lymphoma Project




Arushi Khurana, MBBS

Mayo Clinic, Rochester

CLARENCE G. HENRY, JR. MEMORIAL SCHOLAR

Lymphoma Focus: Diffuse large B-cell lymphoma



Erin Mulvey, MD

Weill Cornell Medicine

PEYKOFF INITIATIVE SCHOLAR

Lymphoma Focus: Diffuse large B-cell lymphoma, follicular lymphoma




Phil Lange, PhD

The University of North Carolina at Chapel Hill

DR. BRUCE D. CHESON FELLOW

Lymphoma Focus: Post-transplant lymphoproliferative disorders, Hodgkin lymphoma, Burkitt lymphoma



Nicole Prutsch, PhD

Dana-Farber Cancer Institute

POSTDOCTORAL FELLOWSHIP GRANT

Lymphoma Focus: Aggressive T-cell lymphoma, pediatric and adolescent/young adult (AYA) lymphoma




Luis Malpica Castillo, MD

The University of Texas MD Anderson Cancer Center

CHIKE SPRINGER LEGACY SCHOLAR

Lymphoma Focus: B-cell lymphoma, T-cell lymphoma



Jason Romancik, MD

Winship Cancer Institute of Emory University

RUNGE LYMPHOMA PROJECT SCHOLAR

Lymphoma Focus: Follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma




Elisa Mandato, PhD

Dana-Farber Cancer Institute

POSTDOCTORAL FELLOWSHIP GRANT

Lymphoma Focus: Hodgkin lymphoma, diffuse large B-cell lymphoma




Marco Ruella, MD

University of Pennsylvania Perelman School of Medicine

CAREER DEVELOPMENT AWARD

Lymphoma Focus: T-cell lymphoma




Reid Merryman, MD

Dana-Farber Cancer Institute

CAREER DEVELOPMENT AWARD

Lymphoma Focus: Hodgkin lymphoma



Suchitra Sundaram, MD

Memorial Sloan Kettering Cancer Center

LRF SCHOLAR

Lymphoma Focus: Non-Hodgkin B-cell lymphoma




Coraline Mlynarczyk, PhD

Weill Cornell Medicine

LRF SCHOLAR

Lymphoma Focus: Aggressive non-Hodgkin lymphoma, T-cell prolymphocytic leukemia



Brian Sworder, MD, PhD

Stanford University School of Medicine

LRF AMBASSADOR SCHOLAR

Lymphoma Focus: Aggressive non-Hodgkin lymphoma



Patrizia Mondello, MD, PhD

Mayo Clinic, Rochester

PEYKOFF INITIATIVE SCHOLAR

Lymphoma Focus: Follicular lymphoma



FINDING OPPORTUNITY: COMMUNITY EMPOWERMENT

At the core of our mission is our commitment to empowering patients with the knowledge and support they need to make informed decisions about their care. Just as we've found opportunities to connect the scientific community and expand our impact in research, we've led the way toward improved education and patient and caregiver support.

In this era of ever-evolving treatment paradigms coupled with the challenges brought by the COVID-19 pandemic, the need to provide support and the latest evidence-based information to patients and their loved ones is even more critical.



EXPANDING REACH THROUGH VIRTUAL PROGRAMMING


Since the onset of the COVID-19 pandemic, we quickly responded to ensure the lymphoma community still had access to the latest research and treatment information related to their disease. **In 2021, we offered more than 70 patient and professional education programs virtually, all including critical updates on the COVID-19 virus and vaccines**, and we served more than 2 million people through our virtual education programming and digital resources. Our webinar on updates from the 2020 American Society of Hematology (ASH) Meeting and Exposition provided more than 1,000 attendees an opportunity to receive updates on pivotal research studies straight from experts in the field.

CONNECTING THE LYMPHOMA COMMUNITY

A lymphoma diagnosis can bring many emotions and challenges, and we are here to make sure no one goes through their journey alone. **In 2021, our Lymphoma Support Network (LSN) grew by more than 20 percent**, offering more one-to-one peer support to people with lymphoma and their caregivers. More than 7,000 lymphoma survivors and caregivers are part of our LSN community to connect with others, share their personal stories, and offer emotional support.

EASING THE FINANCIAL BURDEN OF TREATMENT

Compared to 10 years ago, lymphoma patients are receiving more expensive chemotherapy, immunotherapy, and other new treatments. Add the financial challenges the COVID-19 pandemic has wrought, patients and their loved ones are dealing with a financial impact never seen before. **In 2021, we provided more than 650 grants through our Patient Aid Grant program, a 50 percent increase over last year.** This program is powered entirely through support from individuals and private foundations who want to pay it forward and support patients during a time of need.



We offered more than

70

patient and professional
education programs

Our Lymphoma Support Network
grew by more than

20%

We provided more than

650

grants through our
Patient Aid Grant program





FINDING OPPORTUNITY: HEALTH EQUITY

Achieving health equity requires the removal of barriers and the creation of opportunities so that every person has access to quality healthcare and the means to be as healthy as possible. We have witnessed this firsthand in service to people with lymphoma and their loved ones.

Our Health Equity Initiative aims to address these barriers and champion systemic changes to the way we educate and inform the lymphoma community. Through guidance from our Scientific Advisory Board (SAB) and partnerships with community organizations and corporations, we've made great strides in 2021 in delivering excellent and evidence-based information to patients in underrepresented and underserved populations and in fostering a more inclusive research community.



COMMUNITY-BASED, PATIENT-CENTERED EDUCATION

Recognizing that patients rely heavily on information available to them to maintain their health and their families' health, it is crucial to ensure that such resources are culturally appropriate, produced in multiple languages, and made available to patients and their loved ones where they are and feel most comfortable receiving such information. **In 2021, we developed education programs and resources in Spanish, including a website, disease-specific fact sheets, and virtual education programs.** These materials help the Spanish-speaking community learn about the diagnosis and treatment of lymphoma from experts and provide access to critical support services, including financial and clinical trial search assistance.

Funded
6 RESEARCHERS
through the
**HEALTH EQUITY
INITIATIVE** in 2021



DIVERSITY IN CLINICAL TRIALS

The COVID-19 pandemic showed how various segments of Americans (racial and ethnic minorities, young people, the elderly, etc.) are impacted differently, and so too is the need to prioritize education and opportunities for these groups. This is true in the case of clinical trials, which are critical to advancing new therapies for the treatment of lymphoma. **In 2021, we prioritized awareness and education around clinical trials by spotlighting information on the topic and on our multilingual Clinical Trials Information Service** in all education programs and materials. As a result, the Clinical Trials Information Service witnessed a 61 percent increase in searches compared to the previous year. In addition to educating patients on clinical trials, we prioritized funding research focused on understanding the drivers of disparities in lymphoma.

REPRESENTATION IN BLOOD CANCER RESEARCH AND CLINICAL CARE

Despite decades of workforce diversity efforts, diversification in medical subspecialties like lymphoma research and clinical care remains a challenge. Long-standing institutional traditions and policies that result in inequity create barriers for underrepresented groups in advancing their medical careers. **In 2021, we continued our focus on ensuring the best and the brightest scientists remain in the field of lymphoma research** and also on advancing advancing opportunities for early-career scientists. As a result, 60 percent of our 2021 Clinical Career Development Award (CDA) and Postdoctoral Fellowship grantees are women.

FINANCIALS

For the fiscal year ending June 30, 2021



● Net assets released from restrictions \$4.3 million [42%]

● Contributions and grants \$3.6 million [36%]

● Special events and revenue \$2.2 million [22%]



● Research \$3.8 million [56%]

● Education programs and patient services \$1.8 million [26%]

● Communications and advocacy \$1.2 million [18%]



● Program services \$6.8 million [74%]

● Fundraising \$1.6 million [17%]

● Administration \$827 thousand [9%]

The Condensed Balance Sheets and Statements of Activities of the Lymphoma Research Foundation as of June 30, 2021, and 2020 have been derived from Lymphoma Research Foundation's audited financial statements. The Lymphoma Research Foundation's complete set of audited financial statements and related information can be found on the Lymphoma Research Foundation's website, lymphoma.org/annualreport. The Financial Statements have been audited by KPMG LLP.

LYMPHOMA RESEARCH FOUNDATION

FINANCIAL REPORTS

(in thousands) as of June 30, 2021

ASSETS	2021	LIABILITIES & NET ASSETS	2021
Cash and cash equivalents	\$ 5,490	Research grants payable	\$ 3,199
Investments	20,747	Refundable advances	766
Contributions and grants receivable	4,580	Accounts payable and accrued expenses	412
Prepaid expenses and other assets	390	Accrued salaries and vacation	211
TOTAL ASSETS	\$ 31,207	TOTAL LIABILITIES	\$ 4,588
		Unrestricted net assets	5,562
		Temporarily restricted net assets	21,057
		TOTAL NET ASSETS	\$ 26,619
		TOTAL LIABILITIES & NET ASSETS	\$ 31,207

LYMPHOMA RESEARCH FOUNDATION

CONDENSED STATEMENT OF ACTIVITIES

(in thousands) as of June 30, 2021

UNRESTRICTED CONTRIBUTIONS & REVENUES	2021		
Special events revenues & contributions	\$ 5,726	Program services	\$ 6,793
Investments & other income	100	Supporting services	2,420
CONTRIBUTIONS & REVENUES	\$ 5,826	TOTAL EXPENSES	\$ 9,213
Net assets released from restrictions	4,265	INCREASE IN UNRESTRICTED NET ASSETS	\$ 878
TOTAL CONTRIBUTIONS & REVENUES	\$ 10,091	INCREASE IN TEMPORARY RESTRICTED NET ASSETS	\$ 7,029
		INCREASE IN NET ASSETS	\$ 7,907

SCIENTIFIC ADVISORY BOARD

The Lymphoma Research Foundation's volunteer Scientific Advisory Board, comprised of 45 world-renowned lymphoma experts, guides the Foundation's research activities, seeking out the most innovative and promising lymphoma research projects for support.

ANDREW D. ZELENETZ, MD, PhD—Chair
Memorial Sloan Kettering Cancer Center

SONALI M. SMITH, MD—Chair-Elect
The University of Chicago

RANJANA ADVANI, MD
Stanford University School of Medicine

ASH A. ALIZADEH, MD, PhD
Stanford University School of Medicine

STEPHEN ANSELL, MD, PhD
Mayo Clinic, Rochester

KRISTIE A. BLUM, MD
Winship Cancer Institute of Emory University

CATHERINE BOLLARD, MD, MBChB
George Washington University
Children's National Medical Center

JENNIFER BROWN, MD, PhD
Dana-Farber Cancer Institute

JAMES CERHAN, MD, PhD
Mayo Clinic, Rochester

ETHEL CESARMAN, MD, PhD
NewYork-Presbyterian Hospital
Weill Cornell Medicine

BRUCE D. CHESON, MD, FACP, FAAAS, FASCO
Past Chair, 2010-2012
LRF, Scientific Advisor

MORTON COLEMAN, MD
Chair, Medical Affiliates Board
NewYork-Presbyterian Hospital
Weill Cornell Medicine

SANDEEP DAVE, MD, MS
Duke University

KIERON M. DUNLEAVY, MD
Georgetown Lombardi Comprehensive
Cancer Center

KOJO S.J. ELENITOBA-JOHNSON, MD
University of Pennsylvania
Perelman School of Medicine

ANDREW M. EVENS, DO, MSc, FACP
Rutgers Cancer Institute of New Jersey

CHRISTOPHER R. FLOWERS, MD, MS
The University of Texas MD Anderson
Cancer Center

JONATHAN W. FRIEDBERG, MD, MMSc
University of Rochester
James P. Wilmot Cancer Institute

LEO I. GORDON, MD, FACP
Past Chair, 2015-2017
Robert H. Lurie Comprehensive Cancer Center
of Northwestern University

THOMAS M. HABERMANN, MD
Immediate Past Chair, 2017-2019
Mayo Clinic, Rochester

STEVEN M. HORWITZ, MD
Memorial Sloan Kettering Cancer Center

ERIC D. HSI, MD
Wake Forest School of Medicine

BRAD S. KAHL, MD
Washington University School of Medicine

KARA KELLY, MD
Roswell Park Comprehensive Cancer Center
University at Buffalo Jacobs School of Medicine

ANN S. LACASCE, MD, MMSc
Harvard Medical School
Dana-Farber Cancer Institute

JOHN P. LEONARD, MD
Past Chair, 2012-2015
NewYork-Presbyterian Hospital
Weill Cornell Medicine

BRIAN K. LINK, MD
University of Iowa

IZIDORE S. LOSSOS, MD
University of Miami Health System
Sylvester Comprehensive Cancer Center

PETER MARTIN, MD
Weill Cornell Medicine

ARI MELNICK, MD
NewYork-Presbyterian Hospital
Weill Cornell Medicine

LINDSAY MORTON, PhD
National Cancer Institute

LAURA PASQUALUCCI, MD
Columbia University
H. Irving Comprehensive Cancer Center

BARBARA PRO, MD
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

KANTI R. RAI, MD
Hofstra Northwell School of Medicine

LISA RIMSZA, MD
Mayo Clinic, Arizona

KERRY J. SAVAGE, MD
British Columbia Cancer

DAVID WILLIAM SCOTT, MBChB, PhD
British Columbia Cancer

LAURIE SEHN, MD, MPH
British Columbia Cancer

MARGARET SHIPP, MD
Harvard Medical School
Dana-Farber Cancer Institute

EDUARDO M. SOTOMAYOR, MD
Tampa General Hospital

CHRISTIAN STEIDL, MD
British Columbia Cancer

JOHN M. TIMMERMAN, MD
UCLA Jonsson Comprehensive Cancer Center

SVEN de VOS, MD, PhD
UCLA Jonsson Comprehensive Cancer Center

HANS-GUIDO WENDEL, MD
Memorial Sloan Kettering Cancer Center

MICHAEL E. WILLIAMS, MD, ScM
University of Virginia Cancer Center

BOARD OF DIRECTORS

STEVEN EICHBERG
Chair
Plymouth, MA

JEFF BLOCK
Vice Chair and Treasurer
San Francisco, CA

KIM METCALF
Vice Chair
Landenberg, PA

LEIGH OLSON
Secretary
Miami Beach, FL

MICHAEL AKINYELE
Upper Marlboro, MD

ERIC COHEN
In Memoriam
Chicago, IL

MORTON COLEMAN,
MD Chair, Medical Affiliates Board
New York, NY

KEVIN FENNESSEY
Naples, FL

MICHAEL FROY
Chicago, IL

TOM GOLDSTONE
New York, NY

KEITH HOOGLAND
Glenview, IL

JOHN LEONARD, MD
Past Chair, Scientific Advisory Board
New York, NY

BOB MCAULEY
Charlottesville, VA

JOHN A. NELSON
Westport, CT

SCOTT PANSKY
Tarzana, CA

STEVEN J. PRINCE
Past Chair
Purchase, NY

MICHAEL WERNER
Immediate Past Chair
Chicago, IL

ANDREW D. ZELENETZ, MD, PhD
Chair, Scientific Advisory Board
New York, NY

MEMBERS EMERITUS

JOSEPH R. BERTINO, MD
In Memoriam
New Brunswick, NJ

ERROL M. COOK
Past Chair
Boca Raton, FL

BARBARA FREUNDLICH
Founder
New York, NY

JERRY FREUNDLICH
Founder and Past Chair
New York, NY

DONNA REINBOLT
Houston, TX

ROBERT WERNER
Aventura, FL

LEADERSHIP DONORS

Thank you to our leadership donors for providing hope to the lymphoma community through their commitment to supporting innovative research and evidence-based educational resources.

ABBVIE, INC
ACROTECH BIOPHARMA, LLC
THE ACTOR'S FUND OF AMERICA
ADAPTIVE BIOTECHNOLOGIES
ADC THERAPEUTICS
AMERICAN BOARD OF INTERNAL MEDICINE
ANONYMOUS
MR. AND MRS. STEVEN ARONOW
ASTRAZENECA
THE DAVID R. AND PATRICIA D. ATKINSON
FOUNDATION
MR. GLENN R. AUGUST
MR. JOHN BALLANTINE
MRS. MARY ELLEN BATZNER AND MR. GERALD D.
BATZNER
MR. AND MRS. MICHAEL BEAURY
BEIGENE
STEVEN BENENSON
MAXA SCHUTZ BANK BERID
BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO)

MR. JEFFREY BLOCK
JULIE BLUME
BRISTOL-MYERS SQUIBB
MR. AND MRS. ROBERT BRITTON
THE BRUNING FOUNDATION
BTG INTERNATIONAL, INC
MRS. CONNIE BULL
MR. SCOTT CARNEY
CELLECTAR BIOSCIENCES, INC
MR. OLIVER CHANG
DR. AND MRS. BRUCE D. CHESON
CHIKI SPRINGER FOUNDATION
BRAD CLARK
CLEARFIELD CAPITAL MANAGEMENT LP
MICHAEL AND PATTY COHEN
MS. JEAN R. COLBERT
JOYCE AND MORTON COLEMAN, MD
SUE AND JIM COLLETTI
CONDON FAMILY FOUNDATION
CONDUIT PHILANTHROPIC FUND

MR. AND MRS. FRED CONROY
GLADYS AND ERROL COOK
MR. AND MRS. LEON COOPERMAN
DAIICHI SANKYO, INC
GLORIA AND SIDNEY DANZIGER FOUNDATION
MR. AND MRS. GARY DAVIS
LAURA DE REITZES
MRS. CORISSA DEROSE
MR. JONATHAN DIESENHAUS
GAIL AND LARRY DOBOSH
MR. AND MRS. HOWARD C. DRAFT
MARGARET D. DUNSTAN
BREECE AND RANDI EHRENBORG
JEAN AND STEVEN EICHBERG
ELI LILLY AND COMPANY
EPIZYME
MR. AND MRS. ROBERT FEILBOGEN
JEFF FELLING
THE FERRIDAY FUND CHARITABLE TRUST
MRS. ARLENE FISCHER

LEADERSHIP DONORS (CONT'D)

NORMAN J. AND DORIS FISHER FOUNDATION
THE ESTATE OF JOAN R. FISHMAN
DR. CHRISTOPHER R. FLOWERS
FOUNDATION MEDICINE, INC
MRS. ROBERTA FRANKLIN
BARBARA AND JERRY FREUNDLICH
LYNN AND MICHAEL FROY
THE FUND FOR BLOOD & CANCER RESEARCH, INC
THE ESTATE OF CINDY L. FURST
GANTCHER FAMILY FOUNDATION
ROBERT AND LINDA GARDNER
GENENTECH
GENMAB
MS. DEBORAH L. GERSH
DAVID AND PATRICIA GIULIANI
MS. NANCY GOLDMAN
TOM AND JENN GOLDSTONE/THE GOLDSTONE FUND
MR. ROBERT GOODMAN AND MS. JAYNE LIPMAN
MR. CHRISTOPHER GORELIK
GRAND STREET FOUNDATION
HARRIET AND SCOTT GREENBERG
THE GRINBERG FAMILY FOUNDATION
DR. AND MRS. THOMAS M. HABERMANN, MD
MR. AND MS. RICK J. HAZAN
MR. AND MRS. GARY D. HIRSCH
MS. LINDA HOFMANN
NORM HUDSON
INCYTE CORPORATION
IVANHOE FAMILY CHARITABLE FUND
MR. ERIC JAFFEE
MS. LAUREN JASINSKI
MS. KATHERINE JOHNSON
JOHNSON & JOHNSON FAMILY OF COMPANIES
JOHNSON & JOHNSON HEALTH CARE SYSTEMS, INC
RENATE JORDAN
JUDITH CARNEY TRUST
MRS. PHYLLIS JUNG
SANDRA KAHN
KARYOPHARM THERAPEUTICS, INC
BARRIE AND GLEN KASSAN
MR. AND MRS. RICHARD KAYNE
MR. LAWRENCE KESTIN
KITE, A GILEAD COMPANY
MRS. CAROLYN KLEIN
MR. AND MRS. THOMAS KNIGHT
MR. AND MRS. JEFFREY P. KRASNOFF
MR. AND MRS. ANDREW KRIEGMAN
MARA AND ANDREW KUPFERBERG
MR. RUSSELL KWIAT
KYOWA KIRIN, INC
LEARNERS EDGE, LLC
DEBORAH LERMAN
LE-VEL BRANDS, LLC.
DR. AND MRS. MICHAEL S. LEVINE

PAUL V. MAJKOWSKI, ESQ.
FRANK MALEY
MALLINCKRODT PHARMACEUTICALS
MRS. BILLI W. MARCUS
ESTATE OF LAWRENCE MASON
DR. AND MRS. ROBERT MASSEY
MR. EDWARD E. MATTHEWS
MR. AND MRS. ROBERT W. MCAULEY
MRS. KARI MCDONOUGH
MD ANDERSON CANCER CENTER
MR. THOMAS G. MENDELL
MERCK & CO., INC
MR. AND MRS. DAVID A. MESSER
KIMBERLY A. METCALF
MR. JOEL B. MEYER
TODD MILLER
MORPHOSYS
MR. AND MRS. EUGENE F. MURPHY
JOHN A. NELSON
THE JEROME AND ELAINE NERENBERG FOUNDATION
NETTIE PRENDERGAST TRUST
THE WILLIAM AND ANITA NEWMAN FOUNDATION
NORTH LAKE FOUNDATION
THE NORTHERN TRUST COMPANY
NORTHWELL HEALTH
NOVARTIS PHARMACEUTICALS CORPORATION
OWEN A. O'CONNOR, M.D., PH.D.
MR. AND MRS. MORRIS W. OFFIT
LEIGH AND CORY OLSON
THE OTTO/WHALLEY FAMILY FOUNDATION, INC
MR. SCOTT PANSKY
THE PARKS FAMILY ENDOWMENT FUND
JOSEPH PARZICK
DR. MARK W. PASMANTIER
ANNE AND STEVE PELLEGRINI
MR. AND MRS. ANDREW PEYKOFF
PFIZER, INC
DAVID AND MIRIAM PHALEN AND THE GRINBERG
FAMILY FOUNDATION
PHARMACYCLICS, INC
RICHARD PHILIPS AND JOANN TUCKER PHILIPS
PHRMA
KIERAN PINNEY
PISANI FAMILY FOUNDATION
ESTATE OF J. PRENDERGA
PRINCE FAMILY FOUNDATION
MR. AND MRS. ROBERT PRUZAN
KANTI R. RAI, MD, MBBS
RED CRANE CHARITABLE FUND
REGENERON PHARMACEUTICALS, INC
DONNA AND PAUL REINBOLT
JUDY AND PAT RIORDAN
ROCKING CHAIR FOUNDATION
PAT AND GLENDA ROGERS

ROPES & GRAY
MRS. PHYLLIS ROSEN
MR. AND MRS. STEVEN E. ROSEN
LOIS AND JERRY ROSENBLUM
MS. MICHELE K. ROSS
MR. AND MRS. ERIC ROTH
ANNE D. AND DAVID B. RUBIN
MR. ROBERT M. RUBIN
RUNGE LYMPHOMA PROJECT
MR. AND MRS. ROBERT SABLowsKY
SANOFI US
MS. BOBBY SARNOFF
MR. AND MRS. BRAD SARNOFF
MS. MONA SARNOFF
MR. AND MRS. NORTON SARNOFF
SEAGEN
BETH SEIBERT
MR. LANCE SHACKWAY
MRS. CASSEY SMITH
SOL GOLDMAN CHARITABLE TRUST
MR. AND MRS. ALBERT SPIELMAN
STARWOOD PROPERTY TRUST
MR. JEFFREY STEDMAN
THE JOHN AND LOUISE STEEGSTRA MEMORIAL FUND
JANE AND JAMES STERN
MS. BARBARA STONE
BYRON STORMS
MR. AND MRS. MAYO S. STUNTZ, JR.
MR. GENE T. SYKES
TAKEDA PHARMACEUTICALS U.S.A., INC
MR. MICHAEL B. TARGOFF
LISA TAVERNA
MS. LAURA COLTON TEPPER
TG THERAPEUTICS, INC
GAYLORD AND DIANE THORMODSGARD
JUSTIN TUOHEY
THE ARMAND J. VAN VELTHOVEN REVOCABLE TRUST
VERASTEM, INC
BRAD VERNACI
MR. BYRON VIELEHR
ELLEN M. WALKER AND THE HONORABLE
PAUL CREDITOR
JEFFREY WARD
LAURA AND MICHAEL WERNER
ROBERT WERNER
MR. BRUCE W. WETZEL
MS. JUDY WHALLEY
MS. SHARON WICKES
DR. AND MRS. MICHAEL E. WILLIAMS
MRS. PENNY WOLF
ANDREA AND BRUCE YABLON
DIANA YADEGAR
DR. ADELAIDE W. ZABRISKIE

CIRCLE OF HOPE

Thank you to our Circle of Hope partners, whose monthly support ensures we can respond to the needs of our community and further groundbreaking research year-round.

JASON ALBANO
GARY S. ANTHONY
ANGELA M. BAGLIONE
MICAH BANNER
KAETHE BIERBACH
CHRISTINE M. BOLANIS
BARBARA G. BORNSTEIN
MARY BRADY
ARLENE R. BRUSKIN
STEVEN CHUDNICK
ERWIN COHEN
FRANCESCA COHN
MARY R. COLEMAN
FRANCES COLLAZO
TOBY R. DAVIDOW
PETER DE LIJSER
MICHAEL DEJOY
GUENEVIEVE DEL MUNDO
CAROLYN DOBSON
SHANNON DORSEY
KENNETH P. DUCOTE
SUSANA ENRIQUEZ
FRANK C. FAMIANO
DENNIS S. FERGUSON
THERESA FILLINGER
LUTHER GALES
CYNTHIA GARGAGLIANO

MARGARET A. GHERING
JOHN GREABE
LESLEY NAN HABERMAN
JEANNE HALL
SUE HAMMOND
ELIZABETH HAUGHIE
JOSHUA HERNANDEZ
JUDY HERRIMAN
JUDITH HIGGINS
ROSALIE HISH
AJAY KALRA
KEVIN KELLEY
CHRISTOPHER KINSLER
LUCKY D. KLAESSY
SUSAN POLL KLAESSY
ANDREA KOSTER
LABEL, LLC
RON LAUGHLIN
ANNA LAZZARO
MICHELLE LEBREUX
ERICA LECCE
CASEY LIPSCOMB
LARRY LOOSE
IRA R. LUNSK
BLASE MASINI
ALLISON MASSON
VICTORIA MILLER

SHAW MISEYKO
KIAN JAVADI NAMIN
SHARYN A. NOVOTNY
JOHN O'ROURKE
MARILYN PASKERT
THOMAS PEELE
ELIZABETH A. PICKETT
ERIN POOLE
ARTHUR PRICE
ANGELA REEL
JAMES E. RODGERS
LAUREN ROLAND
MARK SAUERWALD
DONNA ST. GEORGE
SHEILA STAMPER
MICHELLE E. STEINER
DANIELLE SURRA
VINCENT S. TALERICO
ISAAC THOMAS
NANCY J. TRAPP
LAURA WALLENSTEIN
TAMSIN WHITE
ANNELLE WOGGON
ALYSSA ZELLER
MAGGIE ZEQUIRI

THE MASON SOCIETY

Thank you to our Mason Society supporters, whose bequests through bequests create a legacy of hope for the lymphoma community.

DR. SUSAN BAER AND
MR. BRUCE THORNBURG
MS. AMY LOUISE BARNETT
MAXA SCHUTZ BANK BERID
JOHN COHEE, MD
MS. CAROL DAVEY

JEAN AND STEVEN EICHBERG
MR. THOMAS S. LAKRITZ
DEBRA AND MICHAEL LINICK
KIMBERLY A. METCALF
MR. LAWRENCE PRAGER AND
MRS. LINDA MYSZAK

MR. HARRIS M. SHOLMAN
THE ESTATE OF WILLIAM FRANKLIN SPARKS
AND CAROL SPARKS
ANNA M. WHITE



LRF HELPLINE

800-500-9976 (M-F; 9:30am-7:30pm ET)

helpline@lymphoma.org

To create lasting impact:

please donate at lymphoma.org/donate